Barclays’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.64M | Sell |
109,114
-343
| -0.3% | -$17.5K | ﹤0.01% | 1744 |
|
|
2025
Q4 | $5.44M | Sell |
109,457
-121,732
| -53% | -$5.92M | ﹤0.01% | 2154 |
|
|
2025
Q3 | $11M | Buy |
231,189
+90,250
| +64% | +$3.63M | ﹤0.01% | 1595 |
|
|
2025
Q2 | $4.44M | Buy |
140,939
+40,929
| +41% | +$1.31M | ﹤0.01% | 2229 |
|
|
2025
Q1 | $3.28M | Sell |
100,010
-22,839
| -19% | -$809K | ﹤0.01% | 2255 |
|
|
2024
Q4 | $4.44M | Buy |
122,849
+14,061
| +13% | +$495K | ﹤0.01% | 2269 |
|
|
2024
Q3 | $3.39M | Buy |
108,788
+51,005
| +88% | +$1.59M | ﹤0.01% | 2416 |
|
|
2024
Q2 | $1.55M | Sell |
57,783
-22,793
| -28% | -$661K | ﹤0.01% | 2320 |
|
|
2024
Q1 | $2.75M | Sell |
80,576
-22,223
| -22% | -$662K | ﹤0.01% | 2307 |
|
|
2023
Q4 | $2.98M | Buy |
102,799
+47,955
| +87% | +$1.27M | ﹤0.01% | 2566 |
|
|
2023
Q3 | $1.51M | Buy |
54,844
+1,021
| +2% | +$31.1K | ﹤0.01% | 2058 |
|
|
2023
Q2 | $1.62M | Buy |
53,823
+8,585
| +19% | +$300K | ﹤0.01% | 2021 |
|
|
2023
Q1 | $1.64M | Buy |
45,238
+636
| +1% | +$24.5K | ﹤0.01% | 2330 |
|
|
2022
Q4 | $1.59M | Sell |
44,602
-6,337
| -12% | -$220K | ﹤0.01% | 2419 |
|
|
2022
Q3 | $1.72M | Buy |
50,939
+1,449
| +3% | +$47.1K | ﹤0.01% | 1852 |
|
|
2022
Q2 | $1.43M | Sell |
49,490
-17,556
| -26% | -$503K | ﹤0.01% | 2083 |
|
|
2022
Q1 | $2.17M | Sell |
67,046
-10,552
| -14% | -$323K | ﹤0.01% | 1801 |
|
|
2021
Q4 | $2.26M | Buy |
77,598
+15,098
| +24% | +$458K | ﹤0.01% | 2316 |
|
|
2021
Q3 | $1.67M | Buy |
62,500
+28,132
| +82% | +$755K | ﹤0.01% | 2472 |
|
|
2021
Q2 | $1.06M | Sell |
34,368
-72,390
| -68% | -$2.22M | ﹤0.01% | 2628 |
|
|
2021
Q1 | $2.79M | Sell |
106,758
-13,929
| -12% | -$390K | ﹤0.01% | 2004 |
|
|
2020
Q4 | $3.04M | Sell |
120,687
-34,941
| -22% | -$752K | ﹤0.01% | 1915 |
|
|
2020
Q3 | $3.24M | Buy |
155,628
+15,535
| +11% | +$353K | ﹤0.01% | 1710 |
|
|
2020
Q2 | $3.33M | Buy |
140,093
+46,651
| +50% | +$1.03M | ﹤0.01% | 1685 |
|
|
2020
Q1 | $1.68M | Buy |
93,442
+5,507
| +6% | +$116K | ﹤0.01% | 2439 |
|
|
2019
Q4 | $2.09M | Buy |
87,935
+26,507
| +43% | +$644K | ﹤0.01% | 2953 |
|
|
2019
Q3 | $1.69M | Sell |
61,428
-1,701
| -3% | -$50.4K | ﹤0.01% | 3078 |
|
|
2019
Q2 | $2.09M | Sell |
63,129
-18,393
| -23% | -$630K | ﹤0.01% | 2856 |
|
|
2019
Q1 | $2.86M | Buy |
81,522
+12,540
| +18% | +$467K | ﹤0.01% | 2190 |
|
|
2018
Q4 | $2.29M | Sell |
68,982
-11,961
| -15% | -$514K | ﹤0.01% | 2273 |
|
|
2018
Q3 | $4.08M | Buy |
80,943
+56,081
| +226% | +$2.77M | ﹤0.01% | 2022 |
|
|
2018
Q2 | $1.49M | Buy |
24,862
+543
| +2% | +$28.1K | ﹤0.01% | 2851 |
|
|
2018
Q1 | $1.11M | Buy |
24,319
+13,047
| +116% | +$544K | ﹤0.01% | 3077 |
|
|
2017
Q4 | $450K | Buy |
11,272
+7,964
| +241% | +$315K | ﹤0.01% | 3960 |
|
|
2017
Q3 | $133K | Sell |
3,308
-3,547
| -52% | -$154K | ﹤0.01% | 4732 |
|
|
2017
Q2 | $296K | Sell |
6,855
-1,054
| -13% | -$37.5K | ﹤0.01% | 4021 |
|
|
2017
Q1 | $247K | Buy |
7,909
+5,685
| +256% | +$152K | ﹤0.01% | 4102 |
|
|
2016
Q4 | $56K | Sell |
2,224
-18,063
| -89% | -$404K | ﹤0.01% | 5102 |
|
|
2016
Q3 | $501K | Sell |
20,287
-96
| -0.5% | -$2.17K | ﹤0.01% | 3221 |
|
|
2016
Q2 | $415K | Sell |
20,383
-1,966
| -9% | -$34.9K | ﹤0.01% | 3357 |
|
|
2016
Q1 | $335K | Sell |
22,349
-10,070
| -31% | -$131K | ﹤0.01% | 3472 |
|
|
2015
Q4 | $422K | Sell |
32,419
-75,905
| -70% | -$1.17M | ﹤0.01% | 3334 |
|
|
2015
Q3 | $1.52M | Buy |
108,324
+107,021
| +8,213% | +$1.99M | ﹤0.01% | 2359 |
|
|
2015
Q2 | $22K | Sell |
1,303
-13,341
| -91% | -$190K | ﹤0.01% | 5628 |
|
|
2015
Q1 | $175K | Buy |
14,644
+9,676
| +195% | +$91.4K | ﹤0.01% | 4449 |
|
|
2014
Q4 | $40K | Sell |
4,968
-11,894
| -71% | -$99.9K | ﹤0.01% | 5884 |
|
|
2014
Q3 | $135K | Buy |
16,862
+6,651
| +65% | +$60.1K | ﹤0.01% | 5086 |
|
|
2014
Q2 | $102K | Sell |
10,211
-17,837
| -64% | -$159K | ﹤0.01% | 5396 |
|
|
2014
Q1 | $225K | Buy |
28,048
+14,013
| +100% | +$129K | ﹤0.01% | 4672 |
|
|
2013
Q4 | $98K | Sell |
14,035
-4,381
| -24% | -$30.6K | ﹤0.01% | 5659 |
|
|
2013
Q3 | $129K | Buy |
18,416
+14,850
| +416% | +$99.7K | ﹤0.01% | 5416 |
|
|
2013
Q2 | $23K | Buy |
+3,566
| New | +$21K | ﹤0.01% | 6773 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Barclays's SUPN Position: Q1 2026 in Review
Barclays reduced its Supernus Pharmaceuticals (SUPN) stake by 0.31% in Q1 2026, selling an estimated $17.5K and leaving 109,114 shares worth $5.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1744.
Barclays first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $11M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Barclays held 109,114 shares of Supernus Pharmaceuticals worth $5.64M as of Q1 2026.
- Barclays sold 343 Supernus Pharmaceuticals shares in Q1 2026, an estimated $17.5K.
- Supernus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1744 holding.
- Barclays first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Supernus Pharmaceuticals position peaked at $11M in Q3 2025.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.